A commonly used strategy in the development of messenger RNA (mRNA) medicine is based on the destruction of disease-causing mRNA. Achieving the opposite and stabilizing health-promoting mRNA is still a great challenge. A research team has now overcome this challenge: the chemists developed the first active substance that inhibits the deadenylation of mRNA and thus prevents its degradation.